Skip to Content
Merck
All Photos(1)

Documents

Safety Information

A-915

Supelco

7-Aminoclonazepam solution

100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H12ClN3O
CAS Number:
4959-17-5
Molecular Weight:
285.73
EC Number:
200-835-2
MDL number:
MFCD00798467
UNSPSC Code:
41116107
PubChem Substance ID:
329771038
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

100 μg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

NC1=CC=C2C(C(C3=C(Cl)C=CC=C3)=NCC(N2)=O)=C1

InChI

1S/C15H12ClN3O/c16-12-4-2-1-3-10(12)15-11-7-9(17)5-6-13(11)19-14(20)8-18-15/h1-7H,8,17H2,(H,19,20)

InChI key

HEFRPWRJTGLSSV-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This certified Snap-N-Spike® solution is suitable for use as a starting material in calibrators and controls for numerous GC/MS or LC/MS applications in forensic analysis, clinical toxicology and urine drug testing. As a major metabolite, 7-aminoclonazepam may be used to monitor use of the parent drug, clonazepam. Clonazepam, marketed as Klonopin® and Rivotril, is a long-acting benzodiazepine with anxiolytic, anticonvulsant, muscle relaxant, and hypnotic properties.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Klonopin is a registered trademark of Hoffmann-La Roche Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

A-916

7-Aminoclonazepam solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-917

7-Aminoclonazepam-d4 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-924

7-Aminoclonazepam-d4 solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

B-033

Benzodiazepine Multi-component Mixture-8 solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

B-905

Benzodiazepine Internal Standard-3 solution, 0.5-1.0 mg/mL in acetonitrile, ampule of 1.0 mL, certified reference material, Cerilliant®

C-905

Clonazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-906

Clonazepam-d4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-907

Clonazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-047

Flubromazolam solution, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

D-159

Diclazepam solution, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

M-197

Meclonazepam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

M-198

Meclonazepam-D3 solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

D-160

Diclazepam-D4 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

Pictograms

FlameExclamation mark
GHS02,GHS07

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

35.6 °F - closed cup

Flash Point(C)

2 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

PDSCL

Deleterious substance

FSL

Group 4: Flammable liquids
Type 1 petroleums
Hazardous rank II
Water insoluble liquid

ISHL Indicated Name

Substances Subject to be Indicated Names

ISHL Notified Names

Substances Subject to be Notified Names

JAN Code

A-915-CC:
A-915-1ML:4548173316642

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Anni Steentoft et al.
Forensic science international, 184(1-3), 74-79 (2009-01-20)
The benzodiazepine clonazepam is a prescription drug used to treat epilepsy and anxiety. In addition, it is frequently used to treat drug addicts and is itself a popular drug of abuse. In this study, we report the incidence and blood
M Olivera et al.
Drug metabolism letters, 1(1), 3-5 (2007-01-01)
We investigated the role of NAT2 on clonazepam acetylation, using transiently expressed human NAT2 alleles. The NAT25*B and the NAT2*6A variant alleles cause a 20 and 22-fold reduction in the Vmax, respectively. We conclude that NAT2 is responsible for 7-aminoclonazepam
L W Storhaug et al.
Forensic science international, 222(1-3), e33-e35 (2012-07-24)
Urinary analyses of the metabolite 7-aminoclonazepam (7-AC) can be helpful in monitoring drug abuse and in the context of suspected drug-facilitated sexual assaults (DFSA). Only two studies have reported detection times of 7-AC in urine after a single dose of
Mitsutoshi Munakata et al.
Epilepsia, 49(10), 1803-1808 (2008-04-26)
A considerable amount of 7-aminoclonazepam (ACZP), a major metabolite of clonazepam (CZP), is present in the brain during CZP treatment, yet the pharmacological properties of ACZP remain unknown. We investigated the effects of ACZP on the GABA(A) receptor-mediated currents (I(GABA))
J H Edge et al.
Therapeutic drug monitoring, 13(4), 363-368 (1991-07-01)
The purpose of our study was to evaluate the hypothesis that much of the reported variability in the range of concentrations of plasma clonazepam (and also in the range of concentrations of its major metabolite, 7-aminoclonazepam) encountered in pediatric epilepsy
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service